Wikisage, the free encyclopedia of the second generation, is digital heritage
Levetiracetam: Difference between revisions
(→Links) |
(→Links) |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:LeveVITAE_3813.jpg|thumb]] | |||
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat [[epilepsy]]. It is the S-enantiomer of [[etiracetam]], structurally similar to the prototypical nootropic drug [[piracetam]]. | (S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat [[epilepsy]]. It is the S-enantiomer of [[etiracetam]], structurally similar to the prototypical nootropic drug [[piracetam]]. | ||
| Line 11: | Line 12: | ||
In myoclonic astatic epilepsy should be used with caution in children<ref>Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paediatrics 15 6</ref> | In myoclonic astatic epilepsy should be used with caution in children<ref>Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paediatrics 15 6</ref> | ||
Li XC et al. 2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609163/ Clinical characteristics and electroencephalogram analysis of levetiracetam in the treatment of children with febrile seizure recurrence] | |||
Trinka E., et al 2015 | Trinka E., et al 2015 | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559580/pdf/40265_2015_Article_454.pdf Pharmacotherapy for Status Epilepticus] Drugs 75:1499 | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559580/pdf/40265_2015_Article_454.pdf Pharmacotherapy for Status Epilepticus] Drugs 75:1499 | ||
Safraski J.-P.2015 | Safraski J.-P.2015 | ||
| Line 36: | Line 32: | ||
deWolfe & Szafarski | deWolfe & Szafarski | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750522/pdf/fneur-04-00121.pdf Levetiracetam use in the critical care setting] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750522/pdf/fneur-04-00121.pdf Levetiracetam use in the critical care setting] | ||
Lin CH | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672008/pdf/1471-2377-13-48.pdf Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation] | |||
[https://karmel.miraheze.org/wiki/Levetiracetam Levetiracetam] karmel(es) | |||
==[[ATC]]== | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center> | |||
: [[wikipedia:levetiracetam|levetiracetam]] | |||
<ref>http://www.whocc.no/atc_ddd_index/?code=N03AX14&showdescription=yes</ref></center> | |||
|} | |||
==[[West's syndrome|West syndrome]]== | |||
Mangano S et al. | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672008/pdf/1471-2377-13-48.pdf West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence?] | |||
{{refs}} | |||
{{Wikidata|Q417227}} | {{Wikidata|Q417227}} | ||
[[nl:levetiracetam]] | [[nl:levetiracetam]] | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
Latest revision as of 20:29, 20 March 2023
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat epilepsy. It is the S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.
Levetiracetam inhibits high-voltage-activated calcium channels and reduces calcium release from intraneural stores[1]
Extended release
Links
In myoclonic astatic epilepsy should be used with caution in children[2]
Li XC et al. 2017 Clinical characteristics and electroencephalogram analysis of levetiracetam in the treatment of children with febrile seizure recurrence
Trinka E., et al 2015 Pharmacotherapy for Status Epilepticus Drugs 75:1499
Safraski J.-P.2015
Vrielynck P. Current and emerging treatments for absence seizures in young patients
Jackson J.-L. et al.2015
Caviness J. N. Treatment of myoclonus
deWolfe & Szafarski Levetiracetam use in the critical care setting
Lin CH
Levetiracetam in the Treatment of Epileptic Seizures After Liver Transplantation
Levetiracetam karmel(es)
ATC
West syndrome
Mangano S et al. West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence?
| References: |
|
